Summary
Androgen receptor (AR) expression was retrospectively analysed in 47 primary male breast carcinomas (MBCs) using a monoclonal antibody on formalin-fixed, paraffin-embedded tissues. AR immunopositivity was detected in 16 out of 47 (34%) cases. No association was found with patient age, tumour stage, progesterone receptor (PGR) or p53 protein expression. Well-differentiated MBCs tended to be AR positive more often than poorly differentiated ones (P= 0.08). A negative association was found between ARs and cell proliferative activity: MIB-1 scores were higher (25.4%) in AR-negative than in AR-positive cases (21.11%; P= 0.04). A strong positive association (P= 0.0001) was found between ARs and oestrogen receptors (ERs). In univariate analysis, ARs (as well as ERs and PGRs) were not correlated with overall survival; tumour histological grade (P= 0.02), size (P= 0.01), p53 expression (P= 0.0008) and MIB-1 scores (P= 0.0003) had strong prognostic value. In multivariate survival analysis, only p53 expression (P= 0.002) and histological grade (P= 0.02) retained independent prognostic significance. In conclusion, the lack of association between AR and most clinicopathological features and survival, together with the absence of prognostic value for ER/PGR status, suggest that MBCs are biologically different from female breast carcinomas and make it questionable to use antihormonal therapy for patients with MBC.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Alanko, A., Heinonen, E., Scheinin, T., Tolppanen, E. M. & Vihko, R. (1985). Significance of estrogen and progesterone receptors, disease-free interval, and site of first metastasis on survival of breast cancer patients. Cancer 56: 1696–1700.
Allegra, J. C., Lippman, M. E., Thompson, E. B., Simon, R., Barlock, A., Green, L., Huff, K. K., Do, H. M. & Aitken, S. C. (1979). Distribution, frequency, and quantitative analysis of estrogen, progesterone, androgen, and glucocorticoid receptors in human breast cancer. Cancer Res 39: 1447–1454.
Anelli, T. F., Anelli, A., Tran, K. N., Lebwohl, D. E. & Borgen, P. I. (1994). Tamoxifen administration is associated with a high rate of treatment-limiting symtoms in male breast cancer patients. Cancer 74: 74–77.
Bertuzzi, A., Daidone, M. G., Di Fronzo, G. & Silvestrini, R. (1981). Relationship among estrogen receptors, proliferative activity and menopausal status in breast cancer. Breast Cancer Res Treat 1: 253–262.
Bezwoda, W. R., Hesdorffer, C., Dansey, R., de Moor, N., Derman, D. P., Browde, S. & Lange, M. (1987). Breast cancer in men. Clinical features, hormone receptor staus, and response to therapy. Cancer 60: 1337–1340.
Birrell, S. N., Roder, D. M., Horsfall, D. J., Bentel, J. M. & Tilley, W. D. (1995). Medroxyprogesterone acetate therapy in advanced breast cancer: the predictive value of androgen receptor expression. J Clin Oncol 13: 1572–1577.
Bruce, D. M., Heys, S. D., Payne, S., Miller, I. D. & Eremin, O. (1996). Male breast cancer: clinico-pathological features, immunocytochemical characteristics and prognosis. Eur J Surg Oncol 22: 42–46.
Bryan, R. M., Mercer, R. J., Bennett, R. C., Rennie, G. C., Lie, T. H. & Morgan, F. J. (1984). Androgen receptors in breast cancer. Cancer 54: 2436–2440.
Calandra, R. S., Charreau, E. H., Royer de Giaroli, M. & Baldi, A. (1984). Incidence of estrogen, progesterone and prolactin receptors in human breast cancer. Prog Clin Biol Res 142: 97–108.
Cox, D. R. (1972). Regression models and life tables (with discussion). J R Stat (Series B) 34: 187–220.
Cutuli, B., Lacroze, M., Dilhuydy, J. M., Velten, M., De Lafontan, B., Marchal, C., Resbeut, M., Graic, Y., Campana, F., Moncho-Bernier, V., De Gislain, G., Tortochaux, J., Cuillere, J. C., Reme-Saumon, M., N’Guyen, T. D., Lesaunier, F., Le Simple, T., Gamelin, E., Henry, M. & Berlie, J. (1995). Male breast cancer: results of the treatments and prognostic factors in 397 cases. Eur J Cancer 31A: 1960–1964.
Dawson, P. J., Paine, T. M. & Wolman, S. R. (1992). Immunocytochemical characterization of male breast cancer. Modern Pathol 5: 621–625.
Dixon, W. J., Brown, M. G., Engelman, L., Hill, M. A. & Jennrich, R. I. (1990). BMPD Statistical Software Manual, University of California Press: Berkeley
Elston, C. W. & Ellis, I. O. (1991). Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403–410.
Everson, R. B., Lippman, M. E. & Thompson, E. B. (1980). Clinical correlations of steroid receptors and male breast cancer. Cancer Res 40: 991–997.
Fox, S. B., Rogers, S., Day, C. A. & Underwood, J. C. E. (1992). Oestrogen receptor and epidermal growth factor receptor expression in male breast carcinoma. J Pathol 166: 13–18.
Friedman, M. A., Hoffman, P. G., Dandolos, E. M., Lagios, M. D., Johnston, W. H. & Siiteri, P. K. (1981). Estrogen receptors in male breast cancer: clinical and pathologic correlations. Cancer 47: 134–137.
Gerdes, J., Pickartz, H., Brotherton, J., Hammerstein, J., Weitzel, H. & Stein, H. (1987). Growth fractions and estrogen receptors in human breast cancers as determined in situ with monoclonal antibodies. Am J Pathol 129: 486–492.
Guinee, V. F., Olsson, H., Moller, T., Shallenberger, R. C., van den Blink, J. W., Peter, Z., Durand, M., Dische, S., Cleton, F. J., Zewuster, R., Fang Cui, M., Lane, W. & Richter, R. (1993). The prognosis of breast cancer in males. Cancer 71: 154–161.
Hähnel, R. (1985). Progesterone receptor assay in the management of breast and other cancers. Rev Endocr Relat Cancer 20: 5–11.
Hecht, J. R. & Winchester, D. J. (1994). Male breast cancer. Am J Clin Pathol 102(suppl. 1): 25–30.
Hermanek, P. & Sobin, L. H. (1992). TNM Classification of Malignant Tumours, 4th edn. Springer-Verlag: New York
Hiort, O., Kwan, P. W. L. & DeLellis, R. A. (1988). Immunohistochemistry of estrogen receptor protein in paraffin sections. Am J Clin Pathol 90: 559–563.
Isola, J. J. (1993). Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors. J Pathol 170: 31–35.
Jacobs, T. W., Prioleau, J. E., Stillman, I. E. & Schnitt, S. J. (1996). Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. J Natl Cancer Inst 88: 1054–1059.
Joshi, M. G., Lee, A. K., Loda, M., Camus, M. G., Pedersen, C., Heatley, G. J. & Hughes, K. S. (1996). Male breast carcinoma: an evaluation of prognostic factors contributing to a poorer outcome. Cancer 77: 490–498.
Kaplan, E. L. & Meier, P. (1958). Non parametric estimation for incomplete observations. J Am Stat Assoc 53: 457–481.
Kuenen-Boumeester, V., Van der Kwast, T. H., Claassen, C. C., Look, M. P., Liem, G. S., Klijn, J. G. & Henzen-Logmans, S. C. (1996). The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters. Eur J Cancer 32A: 1560–1565.
Langer, M., Kubista, E., Schemper, M. & Spona, J. (1990). Androgen receptors, serum androgen levels and survival of breast cancer patients. Arch Gynecol Obst 247: 203–209.
Lea, O. A., Kvinnsland, S. & Thorsen, T. (1989). Improved measurement of androgen receptors in human breast cancer. Cancer Res 49: 7162–7167.
McGuire, W. L. & Clark, G. M. (1985). The role of progesterone receptors in breast cancer. Semin Oncol 12(suppl.): 12–16.
Mercer, R. J., Bryan, R. M. & Bennett, R. C. (1984). Hormone receptors in male breast cancer. Aust NZ J Surg 54: 215–218.
Miller, W. R., Telford, J., Dixon, J. M. & Hawkins, R. A. (1985). Androgen receptor activity in human breast cancer and its relationship with oestrogen and progestogen receptor activity. Eur J Cancer Clin Oncol 21: 539–542.
Millis, R. R. (1980). Correlation of hormone receptors with pathological features in human breast cancer. Cancer 46: 2869–2871.
Nomura, Y., Yamagata, J., Takenaka, K. & Tashiro, H. (1980). Steroid hormone receptors and clinical usefulness in human breast cancer. Cancer 46(suppl.): 2880–2883.
Pacheco, M. M., Oshima, C. F., Lopes, M. P., Widman, A., Franco, E. L. & Brentani, M. M. (1986). Steroid hormone receptors in male breast diseases. Anticancer Res 6: 1013–1017.
Pertschuk, L. P., Kim, D. S., Nayer, K., Feldman, J. G., Eisenberg, K. B., Carter, A. C., Rong, Z. T., Thelmo, W. L., Fleisher, J. & Greene, G. L. (1990). Immunocytochemical estrogen and progestin receptor assays in breast cancer with monoclonal antibodies. Cancer 66: 1663–1670.
Pertschuk, L. P., Feldman, J. G., Kim, Y. D., Braithwaite, L., Schneider, F., Braverman, A. S. & Axiotis, C. (1996). Estrogen receptor immunocytochemistry in paraffin embedded tissues with ER1D5 predicts breast cancer endocrine response more accurately than H222Spγ in frozen sections or cytosol-based ligand-binding assays. Cancer 77: 2514–2519.
Pich, A., Margaria, E. & Chiusa, L. (1994). Proliferative activity is a significant prognostic factor in male breast carcinoma. Am J Pathol 145: 481–489.
Pich, A., Margaria, E., Chiusa, L., Ponti, R. & Geuna, M. (1996). DNA ploidy and p53 expression correlate with survival and cell proliferative activity in male breast carcinoma. Hum Pathol 27: 676–682.
Poulin, R., Baker, D. & Labrie, F. (1988). Androgens inhibit basal and oestrogen-induced cell proliferation in the ZR-75-1 human breast cancer cell line. Breast Cancer Res Treat 12: 213–225.
Prioleau, J. E. & Schnitt, S. J. (1995). p53 antigen loss in stored paraffin slides (letter). N Engl J Med 332: 1521–1522.
Ribeiro, G. (1985). Male breast cancer: review of 301 cases from Christie Hospital and Holt Radium Institute, Manchester. Br J Cancer 51: 115–119.
Ribeiro, G. & Swindell, R. (1992). Adjuvant tamoxifen for male breast cancer (MBC). Br J Cancer 65: 252–254.
Rogers, S., Day, C. A. & Fox, S. B. (1993). Expression of cathepsin D and estrogen receptor in male breast carcinoma. Hum Pathol 24: 148–151.
Salvadori, B., Saccozzi, R., Manzari, A., Andreola, S., Conti, R. A., Cusumano, F. & Grassi, M. (1994). Prognosis of breast cancer in males. An analysis of 170 cases. Eur J Cancer 30: 930–935.
Sasano, H., Kimura, M., Shizawa, S., Kimura, N. & Nagura, H. (1996). Aromatase and steroid receptors in gynecomastia and male breast carcinoma: an immunohistochemical study. J Clin Endocrinol Metab 81: 3063–3067.
Scarff, R. W. & Torloni, H. (1968). Histological Typing of Breast Tumours. International histological classification of tumours. No. 2, World Health Organization: Geneva
Soreide, J. A., Lea, O. A., Varhaug, J. E., Skarstein, A. & Kvinnsland, S. (1992). Androgen receptors in operable breast cancer: relation to other steroid hormone receptors, correlations to prognostic factors and predictive value for effect of adjuvant tamoxifen treatment. Eur J Surg Oncol 18: 112–118.
Teller, M. N., Stock, C. C., Stohr, G., Merker, P. C., Kaufman, R. J., Escher, G. C. & Bowie, M. (1966). Biologic characteristics and chemotherapy of 7,12-dimethylbenz-(α)anthracene-induced tumors in rats. Cancer Res 26: 245–252.
Walker, K. J., Bouzubar, N., Robertson, J., Ellis, I. O., Elston, C. W., Blamey, R. W., Wilson, D. W., Griffiths, K. & Nicholson, R. I. (1988). Immunocytochemical localization of estrogen receptor in human breast tissue. Cancer Res 48: 6517–6522.
Weber-Chappuis, K., Bieri-Burger, S. & Hurlimann, J. (1996). Comparison of prognostic markers detected by immunohistochemistry in male and female breast carcinomas. Eur J Cancer 32: 1686–1692.
Wilbur, D. C., Willis, J., Mooney, R. A., Fallon, M. A., Moynes, R. & di Sant’Agnese, A. (1992). Estrogen and progesterone receptor detection in archival formalin-fixed, paraffin embedded tissue from breast carcinoma: a comparison of immunohistochemistry with the dextran-coated charcoal assay. Modern Pathol 5: 79–84.
Williams Jr, W. L., Powers, M. & Wagman, L. D. (1996). Cancer of the male breast: a review. J Natl Med Assoc 88: 439–443.
Willsher, P. C., Leach, I. H., Ellis, I. O., Bell, J. A., Elston, C. W., Bourke, J. B., Blamey, R. W. & Robertson, J. F. (1997). Male breast cancer: pathological and immunohistochemical features. Anticancer Res 17: 2335–2338.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Pich, A., Margaria, E., Chiusa, L. et al. Androgen receptor expression in male breast carcinoma: lack of clinicopathological association. Br J Cancer 79, 959–964 (1999). https://doi.org/10.1038/sj.bjc.6690153
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690153
Keywords
This article is cited by
-
Characterisation of male breast cancer: a descriptive biomarker study from a large patient series
Scientific Reports (2017)
-
Breast cancer: trends in international incidence in men and women
British Journal of Cancer (2014)
-
Clinicopathologic characteristics and survival of male breast cancer
International Journal of Clinical Oncology (2014)
-
Are there biologic differences between male and female breast cancer explaining inferior outcome of men despite equal stage and treatment?!
Strahlentherapie und Onkologie (2012)
-
A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences
Breast Cancer Research and Treatment (2012)